Gilead Sciences, Inc. (GILD) is expected to report quarterly earnings of $1.61 a share on sales of $5.3 billion after the market closes on Thursday, based on a FactSet survey of 23 analysts.
In the same period a year ago, the company posted earnings of $1.48 a share on sales of $5.1 billion.
The stock has fallen 7.2% since the company last reported earnings on Feb. 4.
Quarterly estimates have fallen 1.9 cents a share in the past month.
Gilead Sciences is currently trading at a price-to-forward-earnings ratio of 9.6 based on the 12-month estimates of 26 analysts surveyed by FactSet.
Jim Cramer and the AAP team are watching the biotechnology sector. To find out more about what stocks they like in the industry click here now to get more from Action Alerts PLUS.
Introducing TheStreet Courses: Financial titans Jim Cramer and Robert Powell are bringing their market savvy and investing strategies to you. Learn how to create tax-efficient income, avoid top mistakes, reduce risk and more. With our courses, you will have the tools and knowledge needed to achieve your financial goals. Learn more about TheStreet Courses on investing and personal finance here.